Infectious Diseases Pharmacy Specialty Recertification Literature Study: Module 1A-B (Cert # L199140)

ACPE Numbers: Various – see listing below
Release Date: 4/24/2019
Expiration Dates: 10/22/2019
Activity Type: Application-based
CE Credits: 8 hours

Accreditation for Pharmacists

 The American Society of Health-System Pharmacists and American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

The Infectious Diseases Pharmacy Specialty Recertification Literature Study is designed to help board-certified pharmacy practitioners who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS) Board Certification.

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Module 1A – Clostridium difficile Infection Guidelines: This module focuses on guidelines for Clostridium difficile infections. 

Module 1B – Infectious Diseases Potpourri: This module focuses on key studies in the treatment of infectious diseases, including bacteremia, endocarditis, and multidrug resistant gram negative infections. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 8 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

Infectious Diseases Pharmacy Recertification Literature Study Module 1A: Clostridium difficile Infection Guidelines

0204-9999-19-955-H01-P

3

73%

Infectious Diseases Pharmacy Recertification Literature Study Module 1B: Infectious Diseases Potpourri 0204-9999-19-956-H01-P 5

80%

 

Articles and Learning Objectives 

Module 1A - Clostridium difficile Infection Guidelines
0204-9999-19-955-H01-P 

This module focuses on guidelines for Clostridium difficile infections. 

McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66:e1-e48. 

Learning Objectives:

  • Describe the updated Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) clinical practice guidelines for Clostridium difficile infection in adults and children.
  • Make recommendations for the management of Clostridium difficile infection in adults and children.

 

Module 1B – Infectious Diseases Potpourri
0204-9999-19-956-H01-P 

This module focuses on key studies in the treatment of infectious diseases, including bacteremia, endocarditis, and multidrug resistant gram negative infections. 

Holland TL, Raad I, Boucher HW, et al. Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. JAMA. 2018;320(12):1249-1258. doi:10.1001/jama.2018.13155 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the study comparing algorithm-based therapy with usual care for staphylococcal bacteremia.
  • Formulate recommendations for the treatment of staphylococcal bacteremia in adults. 

Iverson K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med 2019; 380:415-24. 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the Partial Oral Treatment of Endocarditis (POET) study.
  • Formulate recommendations for the route of administration of antibiotic therapy for adults with infective endocarditis. 

Canzoneri CN, Akhavan BJ, Tosur Z et al. Follow-up blood cultures in gram-negative bacteremia: are they needed? Clin Infect Dis. 2017; 65:1776-9. 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the study of follow-up blood cultures in patients with bacteremia.
  • Formulate recommendations for the use of follow-up blood cultures in patients with bacteremia. 

Foolad F, Taylor BD, Shelburne SA et al. Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. J Antimicrob Chemother. 2018; 73:2277-83. 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the review of daptomycin use to treat bacteremia caused by vancomycin-resistant Enterococci (VRE).
  • Formulate recommendations for the use of daptomycin to treat patients with bacteremia caused by vancomycin-resistant Enterococci (VRE). 

Harris PNA, Tambyah PA, Lye DC et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018; 320:984-94. 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the study comparing piperacillin-tazobactam with meropenem for the treatment of bloodstream infection caused by Escherichia coli or Klebsiella pneumoniae that is not susceptible to ceftriaxone.
  • Formulate recommendations for antibiotic therapy for patients with bloodstream infection caused by Escherichia coli or Klebsiella pneumoniae that is not susceptible to ceftriaxone. 

Paul M, Daikos GL, Durante-Mangoni E et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018; 18:391-400. 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the study comparing colistin alone with colistin plus meropenem for the treatment of severe infections caused by Gram-negative bacteria not susceptible to carbapenems.
  • Formulate recommendations for the treatment of infections caused by carbapenem-resistant Gram-negative bacteria in adults. 

Yahav D, Franceschini E, Koppel F et al. Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a non-inferiority randomized controlled trial. Clin Infect Dis. 2018 Dec 11. doi: 10.1093/cid/ciy1054. [Epub ahead of print] 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the study comparing 14 days with 7 days of antibiotic treatment for uncomplicated gram-negative bacteremia.
  • Formulate recommendations for antibiotic treatment for uncomplicated gram-negative bacteremia in hospitalized patients. 

Faculty

Monique Bidell, Pharm.D., BCPS
Assistant Professor of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, NY 

Kevin Garey, Pharm.D., M.S., FASHP*
Professor and Chair
University of Houston
Houston, Texas 

Twisha Patel, Pharm.D., BCIDP, BCPS
Clinical Pharmacist Specialist, Antimicrobial Stewardship/Infectious Diseases
Michigan Medicine
Ann Arbor, MI 

Jason Schafer, Pharm.D., M.P.H., AAHIVP, BCPS*
Associate Professor, Department of Pharmacy Practice
Jefferson College of Pharmacy, Thomas Jefferson University
Philadelphia, Pennsylvania 

Kayla Stover, Pharm.D., BCIDP, BCPS-AQ ID, FCCP, FIDSA
Associate Professor
University of Mississippi School of Pharmacy
Jackson, MS 

* Content Matter Experts 

Reviewers

Susan R. Dombrowski, B.S. Pharm., M.S.
Kristi N. Hofer, Pharm.D. 

Field Testers

Hossam Abed, Pharm.D.,BCPS,BCIDP
Lisa Avery, Pharm.D. BCPS BCIDP
Jessica Clark, Pharm.D., BCIDP
Matthew Crotty, Pharm.D., BCIDP
Tiffany Dickey, Pharm.D., BCIDP
Laura Hodge, Pharm.D. BCIDP
Melissa Holloway, Pharm.D., BCIDP, BCPS
Rebecca Jayakumar, Pharm.D., BCIDP
Helen Lee, Pharm.D, BCPS-AQ ID, BCIDP
Tara Lines, Pharm.D., BCIDP
Adrienne Ma, BCIDP
Christine MacBrayne, Pharm.D., MSCS, BCIDP
Neha Manchandia,  Pharm.D., BCIDP
Lauren McDaniel, Pharm.D., BCIDP
Jessica Miller, Pharm.D., BCIDP
Christine Ondro, B.Sc., B.Sc. (Pharmacy), Pharm.D., BCPS, BCIDP
Yanina Pasikhova, Pharm.D., BCPS AQ-ID, BCIDP
Irina Rajakumar, BScPhm, ACPR, BCIDP
Leonor Rojas, Pharm.D., BCPS, BCIDP
Tonya Scardina, Pharm.D., BCPS, BCIDP
Mary Ullman, Pharm.D., BCPS, BCIDP
Linda Yang, Pharm.D., BCPS, BCIDP 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP, and are required to disclose any relevant financial relationships with commercial interests. ASHP and aCCP identify and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Kevin Garey: Merck & Co., Research grant recipient
  • Jason Schafer: Merck & Co, Research grant recipient; Theratechnologies, Advisory Board
  • All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activity consists of audio/ video/PDF files, an attestation statement, assessment, and activity evaluation. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessment
  • Complete the evaluation
  • Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Note: Learner must complete and pass the assessment in order to claim continuing pharmacy education credit. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP.